Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies

J Rheumatol Suppl. 1980;6:12-9.

Abstract

The pharmacokinetics of benoxaprofen in therapeutic doses of 400 or 600 mg as a solution, capsule or tablet were determined in 44 men after single or multiple doses. The plasma levels of the drug after oral administration of a solution best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model. The plasma elimination half-life of the drug, when in solid dosage form, was found to be in the range of 19-26 h, justifying once-a-day dosage. Steady state levels of benoxaprofen were obtained after the 5th dose of a 400 mg capsule every 24 h.

MeSH terms

  • Administration, Oral
  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / blood
  • Anti-Inflammatory Agents / metabolism*
  • Aspirin / pharmacology
  • Benzoxazoles / administration & dosage
  • Benzoxazoles / blood
  • Benzoxazoles / metabolism*
  • Capsules
  • Drug Interactions
  • Humans
  • Intestinal Absorption
  • Kinetics
  • Male
  • Middle Aged
  • Particle Size
  • Propionates / administration & dosage
  • Propionates / blood
  • Propionates / metabolism*
  • Solutions
  • Stereoisomerism
  • Tablets

Substances

  • Anti-Inflammatory Agents
  • Benzoxazoles
  • Capsules
  • Propionates
  • Solutions
  • Tablets
  • benoxaprofen
  • Aspirin